Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,109.14
(
0.00%
)
US TECH 100
25,935.60
(
0.25%
)
Dow Jones
49,447.43
(
0.00%
)
Brent Oil
91.72
(
1.15%
)
Bitcoin
76,061.70
(
0.22%
)
News Focus
News Focus
Post# of 257432
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 69789

Wednesday, 12/10/2008 1:54:13 AM

Wednesday, December 10, 2008 1:54:13 AM

Post# of 257432
>…because the FDA may treat these old/new patents as late listed ones.<

The new law presumably covers this scenario. However, I haven’t read it in detail and don’t intend to.

My interest in MRX is on the cosmetic side rather than the derm side. I don’t especially care what happens with the Solodyn patent, although it is instructive to watch how it unfolds.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today